Fujirebio completes Innogenetics acquisition
This article was originally published in The Gray Sheet
Executive Summary
Japanese diagnostics firm Fujirebio closes $112 million purchase of Belgian specialty diagnostics firm Innogenetics from Abbott Sept. 24. Abbott acquired Innogenetics in February as part of its $6.2 billion acquisition of Solvay Pharmaceuticals, but the divestiture was required to gain European Commission approval of the Solvay transaction. The Fujirebio pact was first announced in July. Both Fujirebio and Innogenetics develop diagnostics in areas such as infectious disease, genetic testing, transplantation and neuro-degeneration. Innogenetics also develops oncology tests, and has a special focus on molecular diagnostics and multiparameter testing